Lowenstein represented Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix), a clinical-stage biopharmaceutical company, in the acquisition of a new research and development center (RDC) located in Frederick, Maryland. The center is expected to accelerate internal discovery and development of vaccines and antiviral drugs against COVID 19, its variants, and other infectious diseases and to increase domestic R&D capability to support U.S. pandemic preparedness.

The approximately 48,000-square-foot facility will support Tonix’s expanding infectious disease pipeline, including a live virus vaccine designed to protect against COVID-19; a live virus vaccine designed to protect against smallpox and monkeypox; a small molecule antiviral under development to treat COVID-19; and a peptide-based skin test to measure functional T cell immunity to SARS-CoV-2.

Tonix purchased the RDC from Southern Research, a collaborating partner on its live virus vaccine development. The center is fully operational with a dedicated staff of scientists and technicians.

Tonix focuses on discovering, licensing, acquiring, and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio is primarily composed of immunology and central nervous system product candidates. Tonix’s immunology portfolio includes a COVID-19 platform of product candidates to prevent and treat COVID-19, to treat long COVID, and to detect functional T cell immunity to COVID-19.

The deal team included Michael J. Lerner, Alex H. Rosenthal, Daniel A. Suckerman, Irina Ishak, Christine Osvald-Mruz, and James C . Shehan.

About Lowenstein Sandler LLP
Lowenstein Sandler is a national law firm with over 350 lawyers based in New York, New Jersey, Palo Alto, Utah, and Washington, D.C. The firm represents leaders in virtually every sector of the global economy, with particular emphasis on investment funds, life sciences, and technology. Recognized for its entrepreneurial spirit and high standard of client service, the firm is committed to the interests of its clients, colleagues, and communities. 

Contact(s):
Stephen J. Kimmerling
Director, Marketing Communications
Lowenstein Sandler LLP
T: +1 973.597.6176
E: [email protected]